American Society of Hirudotherapy

Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors

Translational study published in Nature Communications (2021)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Preclinical (animal)Drug DevelopmentGenomics & ProteomicsSalivary PharmacologyKoh CY et al. · Nature Communications, 2021

Abstract

Despite their limitations, unfractionated heparin (UFH) and bivalirudin remain standard-of-care parenteral anticoagulants for percutaneous coronary intervention (PCI). We discovered novel direct thrombin inhibitors (DTIs) from tick salivary transcriptomes and optimised their pharmacologic activity. The most potent, ultravariegin, inhibits thrombin with a Ki of 4.0 pM, 445-fold better than bivalirudin. Unexpectedly, despite their greater antithrombotic effect, variegin/ultravariegin demonstrated less bleeding, achieving a 3-to-7-fold wider therapeutic index in rodent thrombosis and bleeding models. When used in combination with aspirin and ticagrelor in a porcine model, variegin/ultravariegin reduced stent thrombosis compared with antiplatelet therapy alone but achieved a 5-to-7-fold lower bleeding time than UFH/bivalirudin. Moreover, two antibodies screened from a naïve human antibody library effectively reversed the anticoagulant activity of ultravariegin, demonstrating proof-of-principle for antidote reversal. Variegin and ultravariegin are promising translational candidates for next-generation DTIs that may reduce peri-PCI bleeding in the presence of antiplatelet therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmblyommaAnimalsAntibodiesAnticoagulantsAntidotesAntithrombinsAspirinDrug DevelopmentDrug DiscoveryFemaleFibrinolytic AgentsGene LibraryHeparinHirudinsHumansMalePeptide FragmentsPercutaneous Coronary InterventionProteomicsRatsRats, Sprague-DawleyRecombinant ProteinsSwineThrombinThrombosisTicksTranscriptome

Summary

Ultravariegin, a direct thrombin inhibitor discovered from tick salivary transcriptomes, inhibited thrombin with a Ki of 4.0 pM, 445-fold better than bivalirudin, and together with variegin showed a 3-to-7-fold wider therapeutic index in rodent models; two human antibodies reversed its anticoagulant activity.

Context

This study describes the discovery and optimization of novel direct thrombin inhibitors (variegin and ultravariegin) derived from tick salivary transcriptomes, not from leeches. Ultravariegin inhibits thrombin with a Ki of 4.0 pM (445-fold better than bivalirudin) and demonstrated a 3-to-7-fold wider therapeutic index in rodent thrombosis and bleeding models, with reduced stent thrombosis and shorter bleeding times in a porcine model using aspirin and ticagrelor; two human antibodies reversed its activity as proof-of-principle antidotes. While no leeches are involved, this work pertains to hematophagous-animal-derived anticoagulants, a domain overlapping with leech-derived therapeutics. The study involves no leeches or leech-derived compounds, and all data are preclinical (rodent and porcine models).

Citation

Reference (Vancouver style)

Koh CY, Shih N, Yip CYC, Li AWL, Chen W, Amran FS, et al. Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors. Nat Commun. 2021;12(1):6912. doi:10.1038/s41467-021-27275-8. PMID: 34824278

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.